Vote tally
quorum 2/3Description
RESOLUTION QUESTION: What are the optimal therapeutic targets for preventing TDP-43 neurotoxicity versus pathological aggregation? EMPIRICAL MILESTONES: • Comparative efficacy study of TDP-43 function restoration (antisense oligonucleotides targeting splicing) vs aggregation prevention (small molecule disaggregases) in iPSC-derived neurons from ALS/FTLD • Survival assay (ATP content and LDH release) at 21 days post-treatment identifies which strategy achieves >=50% neuroprotection • Pharmacokinetic analysis of blood-brain barrier penetration for aggregation inhibitors confirms brain exposure at effective concentrations This market resolves YES when the primary empirical milestone is met with peer-reviewed publication and independent replication.
Rationale
Domain: neurodegeneration. Priority score: 0.86. Importance: 0.88. Tractability: 0.82. SCIENTIFIC RATIONALE: The abstract mentions therapeutic approaches targeting both TDP-43 function restoration and aggregation prevention, but doesn't clarify which strategy is more effective or how to optimize target selection. This gap hampers rational therapeutic development for TDP-43 proteinopathies. Gap type: open_ RESOLUTION TIMELINE: 18–36 months. Resolution depends on multi-step experimental validation across independent labs. LMSR LIQUIDITY RECOMMENDATION: 100 tokens. Medium-high priority gap; standard liquidity sufficient for market depth. Initial b-parameter should be set to token_cost/100 = 1.0 for LMSR scoring rule.
Pricing semantics
continuous_probability
Proposal cost: 100 tokens